Abstract: Disclosed is a novel dye for use in a photoelectronic device, wherein the photoelectronic device is comprised of a photoanode comprising the dye. According to the novel dye, the dye is derived through the introduction of a group which narrows the dihedral angle of the dye ligand as well as through the introduction of conjugated groups. Since the dye has improved light sensitivity and absorption properties, it can be used to fabricate a photoelectronic device with high power conversion efficiency.
Type:
Grant
Filed:
June 4, 2007
Date of Patent:
January 4, 2011
Assignee:
Samsung Electronics Co., Ltd.
Inventors:
Byung Hee Sohn, Sang Cheol Park, Won Cheol Jung, Jung Gyu Nam, Young Jun Park, Eun Sung Lee
Abstract: A compound of the formula I or I?, where the radicals R1 are each, independently of one another, a hydrogen atom or C1-C4-alkyl and R?1 is C1-C4-alkyl; X1 and X2 are each, independently of one another, a sec-phosphino group; R2 is (1) hydrogen, (2) R01R02R03Si—, (3) C1-C18-acyl substituted with halogen, hydroxyl, C1-C8-alkoxy or R04R05N—, or (4) R06—X01—C(O)—; R01, R02 and R03 are each, independently of one another, C1-C12-alkyl, unsubstituted or C1-C4-alkyl- or C1-C4-alkoxy-substituted C6-C10-aryl or C7-C12-aralkyl; R04 and R05 are each, independently of one another, hydrogen, C1-C12-alkyl, C3-C8-cycloalkyl, C6-C10-aryl or C7-C12-aralkyl, or R04 and R05 together are trimethylene, tetramethylene, pentamethylene or 3-oxapentylene; R06 is C1-C18-alkyl, unsubstituted or C1-C4-alkyl- or C1-C4-alkoxy-substituted C3-C8-cycloalkyl, C6-C10-aryl or C7-C12-aralkyl; X01 is —O— or —NH—; T is C-bonded C3-C20-heteroarylene; v is 0 or an integer from 1 to 4; X1 in the heteroring of the heteroarylene is bound in the orth
Type:
Grant
Filed:
April 19, 2006
Date of Patent:
January 4, 2011
Assignee:
Umicore AG & Co., KG
Inventors:
Martin Kesselgruber, Marc Thommen, Matthias Lotz
Abstract: A process for preparing cabergoline (I) from ergoline-8?-carboxylic acid ester (XIII) comprising the following steps. (XIII), (XVI), (XVII), (XVIII), (XIX), (I). The present case also relates to the intermediates (XVI), (XVII), (XVIII) and (XIX) as well as the polymorphic amorphous form of Cabergoline (I) and the production thereof.
Type:
Grant
Filed:
March 2, 2005
Date of Patent:
December 28, 2010
Assignee:
Richter Gedeon Vegyeszeti Gyar RT
Inventors:
Janos Galambos, Laszlo Czibula, Ferenc Sebök, Sandorné Balint, Ferencné Kassai, Gyorgyi Ignaczné Szendrei, Adam Demeter
Abstract: Improved analgesic oxymorphone hydrochloride contains less than 10 ppm of alpha, beta unsaturated ketones and pharmaceutical preparations comprising such oxymorphone hydrochloride. The oxymorphone hydrochloride is produced by reducing a starting material oxymorphone hydrochloride using gaseous hydrogen and under specified acidity, solvent system and temperature conditions. A specific polymorph of oxymorphone hydrochloride may be obtained by hydration.
Type:
Grant
Filed:
October 3, 2007
Date of Patent:
December 14, 2010
Assignee:
Johnson Matthey Public Limited Compnay
Inventors:
Jen-Sen Dung, Erno M. Keskeny, James J. Mencel
Abstract: Compounds active on the receptor protein tyrosine kinases c-kit and c-fms are provided herewith. Also provided herewith are compositions useful for treatment of c-kit mediated diseases or condition and c-fms-mediated diseases or condition, and methods for the use thereof.
Type:
Grant
Filed:
May 16, 2006
Date of Patent:
December 7, 2010
Assignee:
Plexxikon, Inc.
Inventors:
Chao Zhang, Jiazhong Zhang, Prabha N. Ibrahim, Clarence R. Hurt, Rebecca Zuckerman, Dean R. Artis, Ryan Bremer, Wayne Spevak, Guoxian Wu, Hongyao Zhu
Abstract: The present invention provides compounds of formula I: These compounds, and pharmaceutically acceptable compositions thereof, are useful generally as kinase inhibitors, particularly as inhibitors of PRAK, GSK3, ERK2, CDK2, MK2, SRC, SYK, and Aurora-2. Accordingly, compounds and compositions of the invention are useful for treating or lessening the severity of a variety of disorders, including, but not limited to, heart disease, diabetes, Alzheimer's disease, immunodeficiency disorders, inflammatory diseases, allergic diseases, autoimmune diseases, destructive bone disorders such as osteoporosis, proliferative disorders, infectious diseases and viral diseases.
Type:
Grant
Filed:
August 20, 2007
Date of Patent:
November 30, 2010
Assignee:
Vertex Pharmaceuticals Incorporated
Inventors:
Alex Aronov, David J. Lauffer, Huan Qiu Li, Ronald Charles Tomlinson, Pan Li
Abstract: Disclosed herein are novel zinc ionophores, zinc chelators and/or zinc complexes with enhanced aqueous solubility. Methods of treating cancer using at least one zinc ionophore and/or zinc chelator are also disclosed. Also disclosed herein are compositions and methods for treating cancer with combination therapy using at least one texaphyrin metal complex and at least one zinc ionophore or the respective pharmaceutically acceptable derivatives or salts thereof.
Abstract: The present invention is directed to processes for the synthesis of morphinans. In particular, a process for cyclizing a ?,?-bicyclic ketone compound to form a nordihydrothebainone product using the Grewe cyclization reaction is improved by forming a reaction mixture comprising a ?,?-bicyclic ketone compound, a cyclizing acid and a water scavenging cyclization additive. In one embodiment, the Grewe transformation occurs in the presence of an acid anhydride as the cyclization additive. Further, the present invention is directed to processes for converting ?,?-bicyclic ketone compounds (e.g., by-products of the Grewe cyclization reaction) to ?,?-bicyclic ketone compounds, wherein the ?,?-bicyclic ketone compounds may be recovered to further undergo Grewe cyclization and form the nordihydrothebainone product.
Type:
Grant
Filed:
February 23, 2006
Date of Patent:
November 23, 2010
Assignee:
Mallinckrodt Inc
Inventors:
Peter Xianqi Wang, Frank W. Moser, Gary L. Cantrell, Jian Bao
Abstract: Novel opiate intermediate compositions and methods of synthesis that include changing the substitution pattern on the aromatic ring of the pre-Grewe intermediate are provided. The intermediates are morphinane derivatives of formula (10), wherein X is a F or Cl and R is selected from the group consisting of an H, alkyl, aryl, acyl, formyl, COR?, CONHR?, COOR, Bn(benzyl), alkyl(methyl), and sulfonamide SO2CH2COPh.
Type:
Grant
Filed:
October 21, 2005
Date of Patent:
November 16, 2010
Assignee:
Mallinckrodt Inc.
Inventors:
Peter Xianqi Wang, Frank W. Moser, Gary L. Cantrell, Daniel P. Magparangalan
Abstract: The present invention relates to compounds useful for measuring aromatase activity. The invention further provides methods for measuring aromatase activity and for screening test agents which modulate aromatase activity. A kit is also provided for use in such screening methods.
Type:
Grant
Filed:
July 30, 2004
Date of Patent:
November 9, 2010
Assignee:
GE Healthcare Limited
Inventors:
John Gerard Whateley, Rahman Aziz Ismail, Peter Gordon Laughton
Abstract: A compound and methods of making thereof having the structure shown below is disclosed. Each Ar is an aromatic group. Each M is palladium, platinum, or rhenium. At least one X in the compound has an aliphatic having at least 1 carbon atom. Each x, each y, and each z is an integer greater than or equal to zero. Each m is an integer greater than or equal to one. n is an integer greater than or equal to three.
Type:
Grant
Filed:
January 23, 2009
Date of Patent:
November 2, 2010
Assignee:
The United States of America as represented by the Secretary of the Navy
Inventors:
Devanand K Shenoy, Enrico Dalcanale, Sander Willems, Marco Busi
Abstract: The present invention relates to compounds for the inhibition of poly(ADP-ribose) polymerase (PARP). In some embodiments, the compounds have the Formula: wherein the constituent variables are as defined herein. The invention further provides methods for the use of the compounds disclosed herein.
Abstract: This invention relates to electroluminescent metal complexes with triazoles and benzotriazoles, respectively of the formula (I) a process for their preparation, electronic devices comprising the metal complexes and their use in electronic devices, especially organic light emitting diodes (OLEDs), as oxygen sensitive indicators, as phosphorescent indicators in bioassays, and as catalysts.
Type:
Grant
Filed:
June 20, 2005
Date of Patent:
October 26, 2010
Assignee:
Ciba Specialty Chemicals Corp.
Inventors:
Thomas Schäfer, Kristina Bardon, Beat Schmidhalter, Roger Prétôt
Abstract: The present invention describes new types of metal complexes. Such compounds can be used as functional materials in a series of different types of applications which can be classified within the electronics industry in the widest sense. The inventive compounds are described by the formulae (1) and (4).
Type:
Grant
Filed:
September 28, 2004
Date of Patent:
October 26, 2010
Assignee:
Merck Patent GmbH
Inventors:
Rocco Fortte, Philipp Stössel, Anja Gerhard, Horst Vestweber
Abstract: Various calcium channel blockers and pharmaceutical compositions containing these compounds are disclosed. Calcium channel blockers are compounds capable of inhibiting calcium ion channels. Methods for preparing calcium channel blockers and their use as calcium channel antagonists are also disclosed.
Abstract: This invention relates to compounds that are activators of glucokinase and thus may be useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial. The compounds are of the general formula (I) wherein A and B are further defined in the application.
Type:
Grant
Filed:
May 24, 2006
Date of Patent:
October 12, 2010
Assignee:
TransTech Pharma, Inc.
Inventors:
Jesper F Lau, Per Vedsø, János Tibor Kodra, Anthony Murray, Lone Jeppesen, Michael Ankersen, Govindan Subramanian, Adnan M. M. Mjalli, Robert Carl Andrews, Dharma Rao Polisetti, Daniel Peter Christen
Abstract: Provided is a light emitting material of which a light emitting device having high luminous efficiency and high stability and capable of being provided at a low cost can be formed. A light emitting material includes the following partial structural formula (1): wherein at least one of R1 to R10 represents a substituent except a hydrogen atom, a total number of benzene ring structures in R1 to R10 is 3 or more, and R1 to R10 include a trifluoromethyl group, or a linear, branched, or cyclic alkyl or alkoxyl group having 2 or more carbon atoms a hydrogen atom of which may be substituted by a halogen atom.
Abstract: Compositions and methods for electrochemical detection of an analyte comprising a transition metal compound wherein M is a metallic element that can form a coordinate bond to nitrogen; R and R? are coordinated to M at their nitrogen atoms; L is a linking ligand; Z is chlorine or bromine; m can be from 1 to 6 and X is an anion, or combination of anions, that balances the charge m. Also provided are electrochemical tags and methods of detection.
Type:
Grant
Filed:
March 27, 2009
Date of Patent:
October 5, 2010
Assignee:
Agency for Science, Technology and Research
Abstract: A thin film transistor comprises a layer of organic semiconductor material comprising a tetracarboxylic diimide naphthalene-based compound having, attached to each of the imide nitrogen atoms, an aromatic moiety, at least one of which moieties is substituted with at least one electron donating group. Such transistors can further comprise spaced apart first and second contact means or electrodes in contact with said material. Further disclosed is a process for fabricating an organic thin-film transistor device, preferably by sublimation deposition onto a substrate, wherein the substrate temperature is no more than 100° C.
Type:
Grant
Filed:
August 21, 2009
Date of Patent:
October 5, 2010
Assignee:
Eastman Kodak Company
Inventors:
Deepak Shukla, Diane C. Freeman, Shelby F. Nelson, Jeffrey T. Carey, Wendy G. Ahearn
Abstract: The present invention is directed to provide 17-cyclopropylmethyl-3,14?-dihydroxy-4,5?-epoxy-6?-[N-methyl-trans-3-(3-furyl)acrylamido]morphinan hydrochloride consistent in quality after production and having high purity. A crystal of 17-cyclopropylmethyl-3,14?-dihydroxy-4,5?-epoxy-6?-[N-methyl-trans-3-(3-furyl)acrylamido]morphinan hydrochloride including a A-form, B-form or C-form crystal thereof, and a process for producing the same are provided.